These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 18005363)

  • 1. Programmed death-1 ligands-transfected dendritic cells loaded with glutamic acid decarboxylase 65 (GAD65) inhibit both the alloresponse and the GAD65-reactive lymphocyte response.
    He FR; Zhu HF; Huang H; Dai YD; Shen X; Wang M; Li L; Xing W; Shen GX
    Clin Exp Immunol; 2008 Jan; 151(1):86-93. PubMed ID: 18005363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerogenic dendritic cells induce antigen-specific hyporesponsiveness in insulin- and glutamic acid decarboxylase 65-autoreactive T lymphocytes from type 1 diabetic patients.
    Segovia-Gamboa N; Rodríguez-Arellano ME; Rangel-Cruz R; Sánchez-Díaz M; Ramírez-Reyes JC; Faradji R; González-Domínguez É; Sánchez-Torres C
    Clin Immunol; 2014 Sep; 154(1):72-83. PubMed ID: 24993292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of programmed death-1 ligand-1 on NIT cells lead to negative regulation of allogeneic lymphocyte activation.
    Wen X; Xu G; Liu J; Zhu H; Dai H; Li L; Hong Y; Yang J; Dai W; Ping L; Shen G
    Cell Immunol; 2010; 263(1):122-8. PubMed ID: 20381020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Forced expression of programmed death-1 gene on T cell decreased the incidence of type 1 diabetes.
    Won TJ; Jung YJ; Kwon SJ; Lee YJ; Lee DI; Min H; Park ES; Joo SS; Hwang KW
    Arch Pharm Res; 2010 Nov; 33(11):1825-33. PubMed ID: 21116786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Up-Regulation of Donor Dendritic Cell PD-L1 Expression Reduced Recipient Lymphocyte Activation and Proliferation In Vitro.
    Li T; Ma R; Zhu JY
    Transplant Proc; 2021 Mar; 53(2):716-723. PubMed ID: 33551184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of Tolerogenic Dendritic Cells by a PEGylated TLR7 Ligand for Treatment of Type 1 Diabetes.
    Hayashi T; Yao S; Crain B; Promessi VJ; Shyu L; Sheng C; Kang M; Cottam HB; Carson DA; Corr M
    PLoS One; 2015; 10(6):e0129867. PubMed ID: 26076454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigen Loading (e.g., Glutamic Acid Decarboxylase 65) of Tolerogenic DCs (tolDCs) Reduces Their Capacity to Prevent Diabetes in the Non-Obese Diabetes (NOD)-Severe Combined Immunodeficiency Model of Adoptive Cotransfer of Diabetes As Well As in NOD Mice.
    Funda DP; Goliáš J; Hudcovic T; Kozáková H; Špíšek R; Palová-Jelínková L
    Front Immunol; 2018; 9():290. PubMed ID: 29503651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory and effector CD4 T cells in nonobese diabetic mice recognize overlapping determinants on glutamic acid decarboxylase and use distinct V beta genes.
    Quinn A; McInerney B; Reich EP; Kim O; Jensen KP; Sercarz EE
    J Immunol; 2001 Mar; 166(5):2982-91. PubMed ID: 11207247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of experimental autoimmune encephalomyelitis by transfer of embryonic stem cell-derived dendritic cells expressing myelin oligodendrocyte glycoprotein peptide along with TRAIL or programmed death-1 ligand.
    Hirata S; Senju S; Matsuyoshi H; Fukuma D; Uemura Y; Nishimura Y
    J Immunol; 2005 Feb; 174(4):1888-97. PubMed ID: 15699115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transplantation of NIT-1 cells expressing pD-L1 for treatment of streptozotocin-induced diabetes.
    Wen X; Zhu H; Li L; Li Y; Wang M; Liu J; Yang D; Liao W; Shen G
    Transplantation; 2008 Dec; 86(11):1596-602. PubMed ID: 19077895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerogenic Dendritic Cells from Poorly Compensated Type 1 Diabetes Patients Have Decreased Ability To Induce Stable Antigen-Specific T Cell Hyporesponsiveness and Generation of Suppressive Regulatory T Cells.
    Dáňová K; Grohová A; Strnadová P; Funda DP; Šumník Z; Lebl J; Cinek O; Průhová Š; Koloušková S; Obermannová B; Petruželková L; Šedivá A; Fundová P; Buschard K; Špíšek R; Palová-Jelínková L
    J Immunol; 2017 Jan; 198(2):729-740. PubMed ID: 27927966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of programmed death ligand 1 in dendritic cells inhibits allogeneic lymphocyte activation in mice.
    Li W; Wang X; Chen R; Zhu H; Chen G; Sun X
    J Surg Res; 2012 Aug; 176(2):e79-87. PubMed ID: 22381170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
    Brown JA; Dorfman DM; Ma FR; Sullivan EL; Munoz O; Wood CR; Greenfield EA; Freeman GJ
    J Immunol; 2003 Feb; 170(3):1257-66. PubMed ID: 12538684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Administration of dendritic cells dual expressing DcR3 and GAD65 mediates the suppression of T cells and induces long-term acceptance of pancreatic-islet transplantation.
    Li Q; Ge C; Liu R; Zhang K; Wu G; Huo W
    Vaccine; 2010 Dec; 28(52):8300-5. PubMed ID: 20969926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses.
    Kitazawa Y; Fujino M; Wang Q; Kimura H; Azuma M; Kubo M; Abe R; Li XK
    Transplantation; 2007 Mar; 83(6):774-82. PubMed ID: 17414712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.
    Fife BT; Pauken KE; Eagar TN; Obu T; Wu J; Tang Q; Azuma M; Krummel MF; Bluestone JA
    Nat Immunol; 2009 Nov; 10(11):1185-92. PubMed ID: 19783989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo.
    Sandner SE; Clarkson MR; Salama AD; Sanchez-Fueyo A; Domenig C; Habicht A; Najafian N; Yagita H; Azuma M; Turka LA; Sayegh MH
    J Immunol; 2005 Mar; 174(6):3408-15. PubMed ID: 15749874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of a broad repertoire of GAD65-specific T-cells in type 1 diabetes patients with graft dysfunction after allogeneic islet transplantation.
    Chujo D; Foucat E; Takita M; Itoh T; Sugimoto K; Shimoda M; Yagi K; Yamagishi M; Tamura Y; Yu L; Naziruddin B; Levy MF; Ueno H; Matsumoto S
    Cell Transplant; 2012; 21(12):2783-95. PubMed ID: 22963904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CTLA4-Ig-modified dendritic cells inhibit lymphocyte-mediated alloimmune responses and prolong the islet graft survival in mice.
    Yang DF; Qiu WH; Zhu HF; Lei P; Wen X; Dai H; Zhou W; Shen GX
    Transpl Immunol; 2008 Jul; 19(3-4):197-201. PubMed ID: 18667318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-1 and its ligands in T-cell immunity.
    Keir ME; Francisco LM; Sharpe AH
    Curr Opin Immunol; 2007 Jun; 19(3):309-14. PubMed ID: 17433872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.